I
Tepkinly is licensed
for 3L+ DLBCL
Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Tepkinly has a conditional marketing authorisation
- further data awaited.
You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for Tepkinly.
Adverse event reporting information can be found at the bottom of this page.
Tepkinly is licensed for 3L+ DLBCL
Tepkinly as monotherapy is indicated for the treatment of adult patients with relapsed or refractory diffuse large B‑cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Tepkinly has a conditional marketing authorisation
- further data awaited.
You are advised to read the Prescribing Information and Summary of Product Characteristics, accessible via the links above, to evaluate patient suitability for Tepkinly.
Adverse event reporting information can be found at the bottom of this page.
Downloadable Resources
Tepkinly dosing and administration guide
A digital guide to dosing and administration of Tepkinly. The guide also provides instructions on how to prepare and store Tepkinly, along with important safety information.
Tepkinly patient information booklet
A booklet for you to download and pass onto your patients who have been prescribed Tepkinly. It contains information that can be referred to throughout treatment, including understanding the Tepkinly treatment routine and possible side effects. This is for use in conjunction with the patient information leaflet.
Tepkinly Preparation and Administration
A guide to the dilution and preparation of the priming (0.16mg), intermediate (0.8mg) doses, and the preparation of the full dose (48mg) of Tepkinly for subcutaneous administration. View the video for a full run through on storage, handling and preparation of Tepkinly, indicated as monotherapy for the treatment of adult patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) after two or more lines of systemic therapy.1
Tepkinly Mode of Action animation
The Tepkinly mechanism of action is explained in this video which shows how by binding simultaneously to CD3 on T cells and CD20 on B cells, epcoritamab forms an immune synapse – inducing cytokine release and T-cell–mediated killing of malignant CD20-expressing cells.1
References
- Tepkinly Summary of Product Characteristics.
UK-EPCOR-240327. Date of preparation: September 2024.
Adverse events should be reported. Reporting forms and information can be found at yellowcard.mhra.gov.uk.
Adverse events should also be reported to AbbVie on GBPV@abbvie.com
